Encapsulation technology, IMMUPEL, by Living Cell Technologies (ASX:LCT) has received an Australian patent , while HealthLinx (ASX:HTX) has received a UK patent for its OvPlex diagnostic technology.
IMMUPEL holds the technology for encapsulation of living cells, which can be transplanted into patients. Since the encapsulated cells are protected from the immune system, there is no need for immunosuppressant drugs. An example of this technology is LCT's DIABECELL, which encapsulates porcine insulin-producing cells, that are later injected into patients with Type 1 diabetes.
AdvertisementHealthLinx (ASX:HTX), the Melbourne-based company has also received patent approval for its OvPlex diagnostic product from the UK patent office. The product basically searches for biomarkers in a sample of blood to detect the presence of ovarian cancer.
P Survey Finds Hospitals are Denying Appointments to Cut Costs Brain Chemicals Vital in Deciding Love Interest M
You May Also Like